At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed breast adenocarcinoma with axillary or internal mammary lymph node involvement documented by routine H&E staining (not immunohistochemistry alone).
- ✓Completed definitive breast surgery: mastectomy with axillary dissection, mastectomy with sentinel node biopsy, lumpectomy with axillary dissection, or lumpectomy with sentinel node biopsy.
- ✓Lumpectomy or mastectomy margins histologically free of invasive breast cancer and DCIS. Margins positive for LCIS are acceptable.
- ✓ECOG performance status 0-2.
- ✕HER2+ breast cancer (3+ by IHC or FISH+).
- ✕Prior cytotoxic chemotherapy, hormonal therapy, or radiation for this breast cancer. Prior anthracycline, anthracenedione, or taxane for any condition is disqualifying. Prior tamoxifen or raloxifene for chemoprevention allowed if discontinued.
- ✕Inflammatory breast disease or fixed axillary nodes (N2) at diagnosis.
- ✕Major surgical procedure within 4 weeks of entry (excluding non-operative biopsy or vascular access device placement).
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Feasibility Trial Incorporating Bevacizumab Into Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Patients With Lymph Node Positive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating doxorubicin hydrochloride, cyclophosphamide, and 7 other interventions for Male Breast Cancer and 3 related conditions. Completed, enrolled 226 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with more than one chemotherapy drug (combination chemotherapy), may be a better way to block tumor growth.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given IV
Given SC
Given SC
Undergo radiation therapy
Given orally
Receive aromatase inhibition therapy